bufogenin has been researched along with Cancer of Ovary in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, F; Jiang, C; Li, Q; Liu, K; Mo, P; Sun, G; Wang, Y; Wei, M; Xu, X; Xu, Y; Zang, J; Zheng, H | 1 |
1 other study(ies) available for bufogenin and Cancer of Ovary
| Article | Year |
|---|---|
Resibufogenin suppresses tumor growth and inhibits glycolysis in ovarian cancer by modulating PIM1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bufanolides; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Glycolysis; Humans; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-pim-1 | 2019 |